Conformationally restricted P13K and mTOR inhibitors

Patent metadata

Field	Value
Publication number	US-9556203-B2
Application number	US-201415026431-A
Country	US
Kind code	B2
Filing date	Oct 3, 2014
Priority date	Oct 4, 2013
Publication date	Jan 31, 2017
Grant date	Jan 31, 2017

Abstract

The invention relates to novel phosphoinositide 3-kinase (PI3K) and mammalian target of rapamycin (mTOR) inhibitor compounds of formula (I) and (II), which are conformationally restricted, and for which the meaning of the substituents are listed in the description. Preferred compounds are those wherein X isoxygen, R 1 is morpholino and R 2 is substituted phenyl or heteroaryl. These compounds are useful, either alone or in combination with further therapeutic agents, for treating disorders mediated by lipid kinases.

First claim

The invention claimed is:

1. Compounds of formula (I) and (II),

and stereoisomers, geometric isomers, tautomers, solvates, and pharmaceutically acceptable salts thereof, wherein
R 1 is

X and Y are independently selected from the group consisting of C(R 8 ) 2 , O, S, SO, SO 2 , and NR 7 ;
R 3x , R 3y , R 3z , R 3p and R 4 are independently selected from the group consisting of hydrogen, D, F, Cl, Br, I, C 1 -C 12 alkyl, C 2 -C 8 alkenyl, C 2 -C 8 alkynyl, —(C 1 -C 12 alkylene)-(C 3 -C 12 carbocyclyl), —(C 1 -C 12 alkylene)-(heterocyclyl having 3-20 ring atoms), —(C 1 -C 12 alkylene)-C(═O)-(heterocyclyl having 3-20 ring atoms), —(C 1 -C 12 alkylene)-(C 6 -C 20 aryl) and —(C 1 -C 12 alkylene)-(heteroaryl having 5-20 ring atoms), —C(C 1 -C 6 alkyl) 2 NR 5 R 6 , —(CR 8 R 9 ) t NR 5 R 6 , —(CR 8 R 9 ) n NR 7 C(═Z)R 8 , (CR 8 R 9 ) n NR 7 S(O) 2 R 5 , —CH(OR 5 )R 6 , —(CR 8 R 9 ) n OR 5 , —(CR 8 R 9 ) n S(O) 2 R 5 , —(CR 8 R 9 ) n S(O) 2 NR 5 R 6 , —C(═Z)R 5 , —C(═Z)OR 5 , C(═Z)NR 5 R 6 , —C(═Z)NR 7 OR 5 , —C(═O)NR 7 S(O) 2 R 5 , —C(═O)NR 7 (CR 8 R 9 ) m NR 5 R 6 , —NO 2 , —NHR 7 , —NR 7 C(═Z)R 5 , —NR 7 C(═Z)OR 5 , —NR 7 C(═Z)NR 5 R 6 , —NR 7 S(O) 2 R 5 , —NR 7 SO 2 NR 5 R 6 , —S(O) 2 R 5 , —S(O) 2 NR 5 R 6 , —SC(═Z)R 5 , —SC(═Z)OR 5 , C 3 -C 12 carbocyclyl, C 2 -C 20 heterocyclyl, C 6 -C 20 aryl, and C 1 —C═NR 7 , OR 5 , —OC(═Z)R 5 , —OC(═Z)OR 5 , —OC(═Z)NR 5 R 6 , and —OS(O) 2 (OR 5 );
R 4x , R 4y , R 4z , and R 4p are independently selected from the group consisting of hydrogen, D, F, Cl, Br, I, C 1 -C 12 alkyl, C 2 -C 8 alkenyl, C 2 -C 8 alkynyl, or one or two of R 4x , R 4y , R 4z , and R 4p are two geminal substituents methyl and the other ones are hydrogen, or R 4x and R 4y , or R 4z and R 4p form together an annullated five- or six-membered carbocyclyl, heterocyclyl, aryl or heteroaryl ring, or R 4x and R 4y form together bridging ethylene or methylene, R 4p and R 4z form together bridging ethylene or methylene, or R 4y and R 4p form together bridging ethylene or methylene;
wherein said alkyl, alkenyl, alkynyl, carbocyclyl, heterocyclyl, aryl and heteroaryl are optionally substituted with one or more groups independently selected from F, Cl, Br, I, CN, CF 3 , NO 2 , oxo, —C(═Z)R 5 , —C(═Z)OR 5 , —C(═Z)NR 5 R 6 , —(CR 8 R 9 ) n NR 5 R 6 , —(CR 8 R 9 ) n C(═Z)NR 5 R 6 , —(CR 8 R 9 ) n C(═Z)OR 5 , —(CR 8 R 9 ) n NR 7 SO 2 R 5 , —(CR 8 R 9 ) n OR 5 , —(CR 8 R 9 ) n R 5 , —(CR 8 R 9 ) n SO 2 R 5 , —NR 5 R 6 , —NR 7 C(═Z)R 5 , —NR 7 C(═Z)OR 5 , —NR 7 C(═Z)NR 5 R 6 , —NR 7 SO 2 R 5 ), —OP(OR 5 )(OR 6 ), SR 5 , —S(O)R 5 , —S(O) 2 R 5 , —S(O) 2 NR 5 R 6 , —S(O)(OR 5 ), —S(O) 2 (OR 5 ), —SC(═Z)R 5 , —SC(═Z)OR 5 , —SC(═Z)NR 5 R 6 , optionally substituted C 1 -C 12 alkyl, optionally substituted C 2 -C 8 alkenyl, optionally substituted C 2 -C 8 alkynyl, optionally substituted C 3 -C 12 carbocyclyl, optionally substituted C 2 -C 20 heterocyclyl, optionally substituted C 6 -C 20 aryl, and optionally substituted C 1 -C 20 heteroaryl;
R 5 , R 6 and R 7 are independently selected from H, D, C 1 -C 12 alkyl, C 2 -C 8 alkenyl, C 3 -C 8 alkynyl, C 3 -C 12 carbocyclyl, C 2 -C 20 heterocyclyl, C 6 -C 20 aryl, and C 1 -C 20 heteroaryl, or R 5 and R 6 together with the nitrogen to which they are attached form a C 3 -C 20 heterocyclic ring optionally containing one or more additional ring atoms selected from N, O or S, wherein said heterocyclic ring is optionally substituted with one or more groups independently selected from oxo, CF 3 , F, Cl, Br, I, C 1 -C 12 alkyl, C 2 -C 8 alkenyl, C 2 -C 8 alkynyl, C 3 -C 12 carbocyclyl, C 2 -C 20 heterocyclyl, C 6 -C 20 aryl and C 1 -C 20 heteroaryl;
R 8 and R 9 are independently selected from H, D, C 1 -C 12 alkyl, and —(CH 2 ) n -aryl, or R 8 and R 9 together with the atoms to which they are attached form a saturated or partially unsaturated C 3 -C 12 carbocyclic ring;
m is 0, 1, 2, 3, 4, 5 or 6;
n is 1, 2, 3, 4, 5, or 6;
t is 2, 3, 4, 5 or 6; and
R 2 is independently selected from the groups consisting of a monocyclic or bicyclic aryl or heteroaryl with 1-6 heteroatoms selected from O, N, S, with 1-4 substituents selected from C 1 -C 4 alkyl, D, F, Cl, Br, I, —OR 5 , —COOH, COORS, —CONR 5 R 6 , —SO 2 NR 5 R 6 , CN, CF 3 , CHF 2 , CFH 2 , OCF 3 , OCOR 5 , NR 7 COR 5 , NR 7 SO 2 R 5 , NR 5 R 6 , SO 2 R 5 , SOR 5 , and SR 5 .

2. The compound of claim 1 wherein R 2 is

wherein the dotted line indicates the point of attachment of R 2 , the amino function may be further substituted with C 1 -C 8 -acyl, oxycarbonyl or aminocarbonyl, and the other substituents have the meaning indicated in claim 1 .

3. The compound of claim 1 wherein R 2 is

wherein the dotted line indicates the point of attachment of R 2 , the amino function may be further substituted with C 1 -C 8 -acyl, oxycarbonyl or aminocarbonyl, and the other substituents have the meaning indicated in claim 1 .

4. The compound of claim 1 wherein R 1 is

optionally further substituted with one or more groups independently selected from D, F, Cl, Br, I, —CH 3 , —CH 2 CH 3 , —CH 2 CH 2 CH 3 , —CH(CH 3 ) 2 , —C(CH 3 ) 3 , —CH 2 OCH 3 , —CHF 2 , —CN, —CF 3 , —CH 2 OH, —CH 2 OCH 3 , —CH 2 CH 2 OH, —CH 2 C(CH 3 ) 2 OH, —CH(CH 3 )OH, —CH(CH 2 CH 3 )OH—CH 2 CH(OH)CH 3 , —C(CH 3 ) 2 OH, —C(CH 3 ) 2 OCH 3 , —CH(CH 3 )F, —C(CH 3 )F 2 , —CH(CH 2 CH 3 )F, —C(CH 2 CH 3 ) 2 F, —CO 2 H, —CONH 2 , —CON(CH 2 CH 3 ) 2 , —COCH 3 , —CON(CH 3 ) 2 , —NO 2 , —NH 2 , —NHCH 3 , —N(CH 3 ) 2 , —NHCH 2 CH 3 , —NHCH(CH 3 ) 2 , —NHCH 2 CH 2 OH, —NHCH 2 CH 2 OCH 3 , —NHCOCH 3 , —NHCOCH 2 CH 3 , —NHCOCH 2 OH, —NHS(O) 2 CH 3 , —N(CH 3 )S(O) 2 CH 3 , ═O, —OH, —OCH 3 , —OCH 2 CH 3 , —OCH(CH 3 ) 2 , —SH, —NHC(═O)NHCH 3 , —NHC(═O)NHCH 2 CH 3 , —S(O)CH 3 , —S(O)CH 2 CH 3 , —S(O) 2 CH 3 , —S(O) 2 NH 2 , —S(O) 2 NHCH 3 , —S(O) 2 N(CH 3 ) 2 , and —CH 2 S(O) 2 CH 3 ;
wherein the dotted line indicates the point of attachment of R 1 , and the other substituents have the meanings indicated in claim 1 , 2 or 3 .

5. The compound of claim 1 wherein R 1 is

wherein the dotted line indicates the point of attachment of R 1 , and the other substituents have the meanings indicated in claim 1 , 2 or 3 .

6. The compound of claim 1 wherein R 1 is morpholino; and the other substituents have the meanings indicated in claim 1 , 2 or 3 .

7. The compound of claim 1 wherein X is O or S.

8. The compound of claim 1 wherein R 3x , R 3y , R 3z , and R 3p are H.

9. The compound of claim 1 wherein R 1 is

10. The compound of any of claim

Assignees

• Univ Basel
• Piqur Therapeutics Ag

Inventors

• Cmiljanovic Vladimir
• Hebeisen Paul
• Jackson Eileen
• Beaufils Florent
• Bohnacker Thomas
• Wymann Matthias

Classifications

• A61P35/00

  Antineoplastic agents · CPC title

• A61P43/00

  Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00 · CPC title

• C07D519/00

  Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00 · CPC title

• C07D498/14 Primary

  Ortho-condensed systems · CPC title

• C07D513/14

  Ortho-condensed systems · CPC title